Nomegestrol acetate

Names

[ Name ]:
Nomegestrol acetate

[Synonym ]:
[(8S,9S,10R,13S,14S,17R)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
EINECS 261-379-8
6-Methyl-3,20-dioxo-19-norpregna-4,6-dien-17-yl acetate
Lutenyl
(17a)-17-Acetyl-6-methyl-3-oxoestra-4,6-dien-17-yl acetate
MFCD00941390
17-Acetoxy-6-methyl-19-norpregna-4,6-diene-3,20-dione
Nomegestrol acetate
Estra-4,6-dien-3-one, 17-acetyl-17-(acetyloxy)-6-methyl-, (17α)-
19-normegestrol acetate

Biological Activity

[Description]:

Nomegestrol acetate is a potent, highly selective progestogen, which is characterized as a full agonist at the progesterone receptor, with no or minimal binding to other steroid receptors, including the androgen and glucocorticoid receptors[1].

[Related Catalog]:

Signaling Pathways >> Others >> Progesterone Receptor

Research Areas >> Endocrinology

[Target]

Progesterone receptor[1]

[References]

[1]. Mueck AO, et al. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids. 2011 May;76(6):531-9.

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
507.3±50.0 °C at 760 mmHg

[ Molecular Formula ]:
C₂₃H₃₀O₄

[ Molecular Weight ]:
370.482

[ Flash Point ]:
219.8±30.2 °C

[ Exact Mass ]:
370.214417

[ PSA ]:
60.44000

[ LogP ]:
3.34

[ Vapour Pressure ]:
0.0±1.3 mmHg at 25°C

[ Index of Refraction ]:
1.554

[ Storage condition ]:
2-8°C

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: RC8899200

CHEMICAL NAME :: 19-Norpregna-4,6-diene-3,20-dione, 17-alpha-hydroxy-6-methyl-, acetate

CAS REGISTRY NUMBER :: 58652-20-3

LAST UPDATED :: 199603

DATA ITEMS CITED :: 6

MOLECULAR FORMULA :: C23-H30-O4

MOLECULAR WEIGHT :: 370.53

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 1050 ug/kg/21D-I

TOXIC EFFECTS :: Endocrine - changes in luteinizing hormone Endocrine - estrogenic Endocrine - effect on menstrual cycle

REFERENCE :: BJOGAS British Journal of Obstetrics and Gynaecology. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.82- 1975- Volume(issue)/page/year: 94,1199,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,657,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,657,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,657,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,657,1984 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 5 mg/kg

SEX/DURATION :: female 4 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,710,1983

Safety Information

[ Symbol ]:

GHS08, GHS09

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H361fd-H400

[ Precautionary Statements ]:
P280

[ Hazard Codes ]:
N

[ Risk Phrases ]:
63-50

[ Safety Phrases ]:
61

[ RIDADR ]:
UN 3077 9 / PGIII

[ RTECS ]:
RC8899200

Articles

Changing convention in combination oral contraceptives: estradiol and nomegestrol acetate in a monophasic 24/4 regimen.

J. Fam. Plann. Reprod. Health Care 39(3) , 211-6, (2013)

Initial oral contraceptive regimens were characterised by high doses of ethinylestradiol (EE) and a progestogen in a 21-day regimen that either included seven additional hormone-free tablets or simply...

A new contraceptive pill containing 17β-estradiol and nomegestrol acetate.

Womens. Health (Lond. Engl.) 9(1) , 13-23, (2013)

Most combined oral contraceptive pills contain ethinyl estradiol (EE) with progestins. In order to minimize the pill's cardiovascular risks, the concept of using 17β-estradiol (E2), the endogenous est...

The “newer” progestogens and postmenopausal hormone therapy (HRT)

J. Steroid Biochem. Mol. Biol. 142 , 48-51, (2014)

• The “newer” progestogens have a high bioavailability. • The “newer” progestogens have a sufficient progestogenic effect. • The “newer” progestogens do not cause undue side effects. • The “newer” pro...